CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Flumazenil +1 moredrug
Likely dose
Flumazenil 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03462641
NCT03462641Phase 2Completed
CompareCT.gov

Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm

University of Michigan·interventional·Posted Mar 12, 2018·Updated Sep 27, 2022

In Brief

A Phase 2 clinical trial evaluating Flumazenil and Placebo for Parkinson Disease. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This arm is a positron emission tomography (PET) biomechanistic GABA-A receptor target engagement study that includes detailed clinical and motor assessments before and after the i.v. administration of 1 mg flumazenil or placebo in Parkinson disease subjects. Each subject will receive 1mg flumazenil or placebo at two visits.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 12, 2018
Enrollment StartMar 9, 2018
Primary CompletionJun 4, 2021
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 8.3 years ago

Interventions

Flumazenildrug

1mg in 10cc normal saline

Placebodrug

10 cc normal saline